Results 111 to 120 of about 73,450 (245)

Anti-granulocyte macrophage colony-stimulating factor autoantibodies: A rising cause of infectious diseases. [PDF]

PLoS Pathog
Wang SY, Lo YF, Tsai YH, Ku CL.
europepmc   +1 more source

DHX15 affects AML1‐ETO9a splicing together with HNRNPL, RBM33 in AML1‐ETO‐positive acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Moderate DHX15, HNRNPL and RBM33 expression drives predominant AML1‐ETO mRNA production, while elevated expression of them promotes generating more AE9a mRNA (Aspartic acid ‐ Glutamic acid ‐ Alanine ‐ Aspartic acid sequence)(messenger ribonucleic acid).
Qiao Liu, Xuechun Wang, Jiqiang Fan, Yi Zheng, Luya Ye, Wenhan Chang, Xianglei Chen, Yuanhua Cai, Xiaolin Lai, Yang Li, Lili Pan, Xiaofan Li, RenJang Lin, Shaoyuan Wang   +13 more
wiley   +1 more source

Understanding the dual role of granulocyte-macrophage colony-stimulating factor in the lung cancer tumor microenvironment and its therapeutic implications. [PDF]

Transl Lung Cancer Res
Wei G, Zhu X, Zhong R.
europepmc   +1 more source

Reduced colony‐stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression

British Journal of Haematology, EarlyView.
Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen, Guillermo Rodriguez‐Real, Alexander F. vom Stein, Luca D. Schreurs, Trong‐Hieu Nguyen, Viktoria Kohlhas, Thanh‐Tung Truong, Maximilian Koch, Sebastian Reinartz, Sumiya Iqbal, Shaista Ilyas, Sanjay Mathur, Nina Reinart, Phuong‐Hien Nguyen, Michael Hallek   +14 more
wiley   +1 more source

Granulocyte-macrophage colony-stimulating factor-containing medium for blastocyst recovery culture: study protocol for a randomized controlled trial (GSET-study). [PDF]

Trials
Kobayashi T, Higuchi K, Okabe-Kinoshita M, Kikuchi K, Kurokawa T, Hatakeyama S, Okubo T, Oikawa S, Suzuki R, Ogawa S, Kuramoto G, Kada A, Shimmura S, Mouri A, Yanaihara A, Segawa T, Yamamoto A, Nishio E, Takahashi K, Nishizawa H, Hamatani T.   +20 more
europepmc   +1 more source

The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders

Brain Pathology, EarlyView.
Aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder is characterized by large tissue destructive lesions in medulla, spinal cord, and optic nerves, with only partial recovery from clinical symptoms, and by lesions with very little tissue destruction and mostly complete recovery from clinical symptoms, as seen in the area postrema ...
Qian Yu, Yoshiki Takai, Naoya Yamazaki, Sarah Brandl, Katharina M. Mair, Thibault Bouderlique, Maria Eleni Kastriti, Igor Adameyko, Romana Höftberger, Markus Reindl, Jan Bauer, Monika Bradl   +11 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor-Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance. [PDF]

MedComm (2020)
Geng S, Yang F, Jia H, Zhao G, Zhao W, Yu J, Zhu H, Cai H, Yang L, Zhang S, Yu F, Jin X, Zhang S, Wang X, Yang Y, Zhang J, Wang B.   +16 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source